Kamada Ltd. (KMDA)
| Market Cap | 267.73M |
| Revenue (ttm) | 103.72M |
| Net Income (ttm) | 4.41M |
| Shares Out | 45.11M |
| EPS (ttm) | 0.09 |
| PE Ratio | 65.22 |
| Forward PE | 80.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,776 |
| Open | 5.88 |
| Previous Close | 5.92 |
| Day's Range | 5.88 - 6.02 |
| 52-Week Range | 5.11 - 8.16 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 11.00 (+85.3%) |
| Earnings Date | n/a |
About KMDA
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat ...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for Kamada stock is "Buy" and the 12-month stock price forecast is 11.00.
News
Kamada Stock Jumps After Acquisition Of Four Plasma-Derived Products
Kamada Ltd (NASDAQ: KMDA) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics. Kamada will pay Saol a $95 million upfront payment and an additional $50 m...
Kamada (KMDA) Reports Q3 Loss, Lags Revenue Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -166.67% and 8.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Kamada: Q3 Earnings Insights
Kamada (NASDAQ:KMDA) reported its Q3 earnings results on Monday, November 22, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Deri...
REHOVOT, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has acquired a portfolio of four U.S. Fo...
Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisit...
REHOVOT, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and nine months ...
Kamada's Earnings: A Preview
Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.
New Strong Sell Stocks for August 25th
BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021
Kamada (KMDA) Q2 Earnings and Revenues Miss Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Ac...
REHOVOT, Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months e...
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children
FORT LEE, N.J. and REHOVOT, Israel, June 2, 2021 /PRNewswire/ -- Kedrion Biopharma and Kamada Ltd.
Kamada (KMDA) Q1 Earnings Top Estimates
Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities
REHOVOT, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three months ended Marc...
Kamada's Earnings Outlook
On Wednesday, May 12, Kamada (NASDAQ:KMDA) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
5 Health Care Stocks Trading with Low Price-Earnings Ratios
As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...
Kamada Reports Top-line Data Of Plasma-Derived IgG Treatment From Early-Stage COVID-19 Trial
Kamada Ltd (NASDAQ: KMDA) has announced top-line results from its Phase 1/2 trial in Israel evaluating plasma-derived hyperimmune globulin (IgG) treatment for COVID-19. Kamada had announced the interim ...
Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) ...
REHOVOT, Israel, March 31, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced top-line results from its Phase 1/2 open-label, single-...
Kamada to Present at the Jefferies Global Plasma Summit
REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will prese...
Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Re...
Transaction Furthers Kamada's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company
Kamada Files Annual Report for the Year Ended December 31, 2020
REHOVOT, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the...
Kamada (KMDA) Misses Q4 Earnings and Revenue Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -42.86% and -4.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Kamada Q4 Earnings
Shares of Kamada (NASDAQ:KMDA) decreased 1.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 69.23% over the past year to $0.04, which missed...
Kamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development A...
REHOVOT, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and 12 months en...
Earnings Preview: Kamada (KMDA) Q4 Earnings Expected to Decline
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2020 Financial Results, and Host Conference Call...
REHOVOT, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quar...